Rapamycin nanoparticles improves drug bioavailability in PLAM treatment by interstitial injection
Pulmonary lymphangiomyomatosis (PLAM) is a rare interstitial lung disease characterized by diffuse cystic changes caused by the destructive proliferation of smooth muscle-like cells or LAM cells. PLAM is more ...